Company Overview
Snapshot
Founded in July 2017 by Daniella Givon, Raanan Margalit, and Nadav Shraibom, DUN T1 operates with 1–10 employees. The company has secured funding across one round, raising $45K from Fundit. This funding supports its work in developing an orally administered drug for type 1 diabetes.
Business overview
DUN T1 is an early-stage R&D company focused on developing an orally administered drug for type 1 diabetes. The company's core technology centers on a novel, patented natural ingredient designed for proactive treatment and early diagnosis. DUN T1 operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development markets, with a focus on patients and pharmaceutical companies.
Log in to access full profile ›Company Intelligence Q&A
- What is DUN T1's primary focus?
- DUN T1 is an early-stage R&D company dedicated to developing an orally administered drug for type 1 diabetes, aiming for a proactive approach to treatment and early diagnosis.
- When was DUN T1 founded and by whom?
- DUN T1 was founded in July 2017 by Daniella Givon, Raanan Margalit, and Nadav Shraibom.
- What is the status of DUN T1's drug development?
- DUN T1 is currently in the R&D product stage, focusing on developing its novel natural ingredient for type 1 diabetes treatment.
- Which sector does DUN T1 operate in?
- DUN T1 operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- How many employees does DUN T1 have?
- DUN T1 operates with 1–10 employees.